Cosmo Pharmaceuticals N.V. (LON:0RGI)

Market Cap	836.34M
Revenue (ttm)	220.63M
Net Income (ttm)	110.18M
Shares Out	n/a
EPS (ttm)	6.71
PE Ratio	7.59
Forward PE	19.18
Dividend	1.73 (3.03%)
Ex-Dividend Date	Jun 4, 2025

Volume	3,729
Average Volume	2,643
Open	56.80
Previous Close	57.19
Day's Range	56.60 - 58.50
52-Week Range	41.65 - 80.50
Beta	1.30
RSI	52.71
Earnings Date	Jul 23, 2025

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delive...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1997
• Employees: 322
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RGI

Financial Performance

Financial numbers in EUR